% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Eggers:843730,
      author       = {Eggers, Carsten and Dano, R. and Schill, J. and Fink, G. R.
                      and Hellmich, M. and Timmermann, L.},
      title        = {{P}atient-centered integrated healthcare improves quality
                      of life in {P}arkinson’s disease patients: a randomized
                      controlled trial},
      journal      = {Journal of neurology},
      volume       = {265},
      number       = {4},
      issn         = {0340-5354},
      address      = {Berlin},
      publisher    = {Springer85301},
      reportid     = {FZJ-2018-01282},
      pages        = {764-773},
      year         = {2018},
      abstract     = {IntroductionImproving quality of life (QoL) is a key issue
                      when dealing with Parkinson’s disease (PD). Integrative
                      care shows potential to achieve improvements in QoL. Here,
                      we analyzed whether a community-based, open-label,
                      integrated approach improves QoL in PD patients.MethodsPD
                      patients were screened for eligibility and evaluated by a
                      university-based PD specialist, a PD nurse, and a general
                      neurologist at a local practice. Patients were randomly
                      assigned to a control group (CG), receiving standard German
                      neurological treatment including a baseline assessment and
                      follow-up visit at 6 months, or an interventional group (IG)
                      who received an individually tailored therapy plan and
                      additional home visits. Patients and investigators were not
                      blinded for either intervention. Primary outcome analysis
                      compared the differential change of PDQ-39 from baseline to
                      6-month follow-up between CG and IG. Between-group changes
                      in mood, motor/non-motor functioning, and cognition were
                      secondary outcomes.Results300 patients were included and
                      randomized equally to IG and CG. 132 IG and 125 CG patients
                      had a valid PDQ-39 at follow-up and qualified for the
                      modified ITT analysis. PDQ-39 improved more in IG compared
                      to CG [2.2 points $(95\%$ CI − 4.4 to 0.1); p = 0.044].
                      Likewise, change scores between IG and CG favored IG for
                      UPDRS III (p < 0.001, mean change 3.3, $95\%$ CI − 4.9 to
                      − 1.7) and PD-NMS (p < 0.001, mean change 11.3, $95\%$ CI
                      − 17.1 to − 5.5).ConclusionsData show that an integrated
                      approach, compared to regular PD care, improves QoL as well
                      as motor and nonmotor PD symptoms over 6 months. Future
                      studies need to address the cost–benefit ratio and whether
                      positive effects can be maintained beyond intervention.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29392459},
      UT           = {WOS:000428928200004},
      doi          = {10.1007/s00415-018-8761-7},
      url          = {https://juser.fz-juelich.de/record/843730},
}